MYSTORY with …
Mano
Berlin
“To Tell the truth, I never came out because i was never hidden in the closet.”
Published: October 2023
There are certainly a multitude of people and events that have marked, educated, shocked and inspired me. My parents and my family are my primary role models. Fortunately, they tought me essential basics such as courage, respect and humility. They nurtured the roots on which I can grow. My parents certainly knew about my homosexuality before me, but they never asked me the question. Out of modesty, fear or respect, I don’t know. Anyway, I like to think it’s out of love. To tell the truth, I never came out because I was never hidden in the closet.
I knew at a very young age that I was different from others, by my physical appearance, my origins and also my attraction to boys.
I am very lucky to have a loving and respectful family. I would like other less fortunate people to access better possibilities.
Today as Doctor of Pharmacy I work at Parexel International as project director for compassionate programs. These programs provide patients with serious or life-threatening conditions access to unapproved products when no comparable alternative treatment options exist – while ensuring patient safety and superior delivery.
I identify as queer and believe that a diverse, equitable and inclusive world leads to better outcomes for and with everyone. It expands access to better health care, creates opportunities and expands human rights for traditionally underrepresented patient groups.
Most if not all clinical trials focus on male/female behaviors against drugs for purposes of safety and efficacy and to better dose patients. Failure to collect gender identity information means that there may be certain diseases, conditions and risk factors that we are not aware of. Unfortunately, traditional study structures, the templates we use for protocols and informed consent documents, and the data we collect are often designed in ways that do not address the specific needs and demographics of the transgender community.
Our priority commitment to patients must motivate us to recruit a diverse group of patients that represent our society. Indeed, we develop methods, trainings and documents to promote and improve the enrollment of LGBT*IQ patients in clinical drug trials and compassionate programs. There is a need to educate healthcare professionals to encourage diverse patients to participate in clinical trials, including transgender and non-binary people.
We need trust and respect of transgender and non-binary communities towards their healthcare professional in the context of clinical research.